Clinical Trials · NCT07207148
People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists
- Phase
- N/A
- Recruitment status
- Recruiting
- Sponsor
- Northwestern University
- Enrollment
- 100
- Start date
- Nov 2025
- Locations
- 1 site, United States
- Primary endpoint
- PIRA